FindTrial
Sign In

Integrated analysis of the IMpower130 and IMpower132 trials

Integrated analysis of the IMpower130 and IMpower132 trials - Integrated analysis of the IMpower130 and IMpower132 trials

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000051330
Enrollment
Unknown
Registered
2023-06-13
Start date
2023-06-19
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

unresectable locally advanced non-squamous non-small cell lung cancer

Interventions

None listed

Sponsors

Chugai Pharmaceutical Co., Ltd
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with non-squamous non-small-cell lung cancer enrolled in Studies IMpower130 and IMpower132 who are judged by the ethics review committee to be eligible for analysis in this study.

Exclusion criteria

Exclusion criteria: Patients with non-squamous non-small-cell lung cancer enrolled in Studies IMpower130 and IMpower132 who are judged by the ethics review committee to be ineligible for analysis in this study.

Design outcomes

Primary

MeasureTime frame
Efficacy (progression-free survival, overall survival, response rate) and safety by subgroup—

Countries

Japan

Contacts

Public ContactYuki Kobayashi

Chugai Pharmaceutical Co., Ltd Medical Affairs Div.

cma-clinicaltrial@chugai-pharm.co.jp03-3273-0866

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026